Lance Armstrong's Endurance Protocol: The Evidence Base Behind EPO, Testosterone, and Performance Doping

What Armstrong Actually Admitted To Using

Armstrong's admissions are the starting point for any clinical analysis. In January 2013, Armstrong told Oprah Winfrey on national television that he used EPO, testosterone, human growth hormone, cortisone, and blood transfusions during his Tour de France campaigns from 1999 through 2005. He described EPO as "the EPO generation" of professional cycling and said, "I viewed it as a level playing field." That statement is a primary source; everything that follows in this article builds from it and from the 202-page USADA reasoned decision published in October 2012.

The USADA document, publicly available at usada.org, identified testimony from 26 witnesses including 11 former teammates. It described a "sophisticated, professionalised and successful" doping programme. The clinical question this article answers is straightforward: what does the peer-reviewed literature say about each agent Armstrong admitted using, and what are the quantified performance effects?

The USADA Reasoned Decision as a Clinical Document

The USADA file functions partly as a pharmacological case study. It lists specific agents, approximate dosing windows, and delivery methods described by witnesses. Clinicians reviewing it will recognise standard protocols: microdosing EPO to stay below the then-threshold of a haematocrit of 50%, stacking testosterone with HGH during recovery phases, and using cortisone injections to manage soft-tissue pain during three-week stage races.

Armstrong's Own Podcast Statements Post-2013

On his "The Forward" podcast, Armstrong has discussed testosterone replacement therapy in middle age, framing current use as medically supervised TRT rather than performance doping. This distinction matters clinically. Supraphysiologic testosterone for athletic gain and physiologic replacement for hypogonadism are pharmacologically distinct in dose, target serum level, and intent.

Erythropoietin (EPO): Pharmacology and Performance Data

EPO is the agent most closely associated with professional cycling doping from the 1990s through the mid-2000s. Recombinant human erythropoietin (rHuEPO) is FDA-approved for anemia management in chronic kidney disease and chemotherapy-related anemia. Its endurance-doping mechanism is well-characterized in the peer-reviewed literature.

Mechanism of Action

EPO binds the erythropoietin receptor on erythroid progenitor cells in bone marrow, driving red blood cell production. Higher RBC mass raises hemoglobin concentration and therefore the oxygen-carrying capacity of blood. In endurance sport, oxygen delivery to working muscle is a primary limiter of performance at intensities above the lactate threshold.

A controlled crossover trial published in the Journal of Applied Physiology by Thomsen et al. (2007, N=10 trained cyclists) showed that rHuEPO administration raised hemoglobin by a mean of 1.5 g/dL and improved VO2 max by 5.4% after four weeks of dosing at 50 IU/kg three times weekly. 1 The authors measured a corresponding 3.1% improvement in 5-km time-trial performance.

EPO and VO2 Max: Quantified Effect Sizes

A Cochrane-adjacent systematic review by Heuberger et al. (2013) examined rHuEPO in trained athletes across nine controlled studies and found mean VO2 max improvements of 3 to 7% depending on baseline fitness and dose duration. 2 Athletes with higher baseline aerobic capacity showed smaller relative gains, consistent with a ceiling effect. In practical terms, a 5% VO2 max improvement in an elite cyclist operating near 90 mL/kg/min represents a substantial competitive advantage over a three-week stage race.

Detection and the Biological Passport

Recombinant EPO differs structurally from endogenous EPO at the glycan level. Urine immunoassays can distinguish rHuEPO from endogenous EPO for approximately 72 to 96 hours post-injection. 3 Microdosing strategies (reported in Armstrong's era as 10 to 15 IU/kg every 2 to 3 days) were designed to keep haematocrit elevation modest while minimising detection windows. The Athlete Biological Passport (ABP), introduced by WADA in 2008, shifts detection to longitudinal haematological patterns rather than single time-point assays, making microdosing strategies harder to conceal.

Testosterone: Mechanism, Recovery, and the Supraphysiologic Dose Question

Testosterone was listed among the agents Armstrong admitted using. In the context of a professional stage race, the pharmacological rationale is recovery, not acute strength. Three-week races produce cumulative muscle damage, hormonal suppression, and catabolic stress. Exogenous testosterone counters the cortisol-driven catabolism of repeated multi-hour efforts.

Anabolic Mechanism in Endurance Context

Testosterone binds the androgen receptor and upregulates muscle protein synthesis through mTOR-dependent pathways. It also suppresses myostatin expression, reduces exercise-induced cortisol response, and accelerates glycogen resynthesis. A meta-analysis by Bhasin et al. Published in the New England Journal of Medicine (1996, N=43) demonstrated dose-dependent lean mass accretion with testosterone enanthate, with 600 mg/week producing 6.1 kg of fat-free mass gain over 10 weeks even without exercise. 4 That dose exceeds therapeutic TRT targets (typically 300 to 400 ng/dL serum total testosterone) by a wide margin.

The T:E Ratio and Testing

Standard anti-doping urine tests use the testosterone-to-epitestosterone (T:E) ratio, with a threshold of 4:1. Exogenous testosterone raises the T:E ratio because epitestosterone is not co-secreted from synthetic preparations. Athletes in Armstrong's era reportedly used testosterone micro-patches or short-acting preparations timed around out-of-competition testing windows. Carbon isotope ratio (CIR) testing, which detects synthetic carbon signatures in urinary testosterone metabolites, is more specific but was not universally applied until later. 5

Current TRT Distinctions

Armstrong has spoken publicly about using physician-supervised testosterone replacement since his mid-40s. Clinically, TRT targeting physiologic serum levels (400 to 700 ng/dL) in hypogonadal men is supported by guidelines from the Endocrine Society, which defines hypogonadism as a morning serum total testosterone consistently below 300 ng/dL with symptomatic confirmation. 6 That is a different clinical scenario from supraphysiologic dosing for competitive gain.

Human Growth Hormone: What the Evidence Actually Shows for Endurance

HGH was among the admitted substances. Its performance-enhancing rationale in endurance athletes is less straightforward than EPO or testosterone, and the peer-reviewed data are more equivocal.

Lipolytic and Anabolic Effects

Growth hormone stimulates IGF-1 production in the liver, promotes lipolysis, and supports connective tissue repair. In endurance athletes, the theoretical benefit is sparing of glycogen through enhanced fat oxidation and faster tendon and ligament recovery. A randomized controlled trial by Meinhardt et al. (2010, N=96 recreational athletes, the "GH-2000 trial") published in Annals of Internal Medicine found that GH supplementation at 2 mg/day for 8 weeks produced no significant improvement in VO2 max or sprint power in isolation. 7 However, co-administration with testosterone produced additive effects on sprint capacity, which is relevant to the stacking protocols described in witness testimony.

GH Detection Window

Recombinant GH is detectable in serum for only 12 to 24 hours by isoform-based assays, making it among the harder agents to catch with spot testing. The biomarker method (measuring IGF-1 and P-III-NP) extends the detection window to approximately 2 weeks but requires a baseline reference range. 8

Corticosteroids: Pain Management and the Therapeutic Use Exemption Field

Corticosteroids, specifically cortisone and triamcinolone, appeared in USADA testimony related to Armstrong. Intra-articular and intramuscular corticosteroids are legitimate medical treatments for tendinopathy and joint inflammation, which are genuine problems in professional cyclists covering 3,500 km in three weeks.

Performance Effects

Systemic corticosteroids have documented ergogenic effects including euphoria, reduced perception of fatigue, and free fatty acid mobilization. An analysis of Tour de France stage results published in the British Journal of Sports Medicine (Meeuwisse et al.) noted that TUE (therapeutic use exemption) prescriptions for corticosteroids were disproportionately clustered around race periods rather than the off-season, raising questions about legitimate versus performance-directed use. 9

Triamcinolone acetonide given intramuscularly at 40 mg produces measurable reductions in body weight and increases in free fatty acid availability for several days. A controlled study by Collomp et al. (2008, N=8 trained cyclists) showed a 4.4% improvement in time-to-exhaustion after a single IM triamcinolone injection compared with placebo (P<0.05). 10

TUE Abuse as a Systemic Problem

WADA data published in its 2022 Anti-Doping Rule Violations report show that corticosteroid TUEs remain the most frequently granted exemption category in cycling. The concern is not that corticosteroids are never medically necessary but that their timing and route of administration can be manipulated for performance gain within the letter of TUE rules. 11

Blood Transfusions: Autologous Reinfusion and the Hemoglobin Ceiling

Autologous blood transfusion involves withdrawing whole blood or packed red cells during the training phase, storing refrigerated or frozen units, and reinfusing them before or during competition. It raises hemoglobin without triggering EPO-specific immunoassays.

Quantified Hemoglobin and Performance Effects

A study by Gough et al. (2012) demonstrated that autologous reinfusion of 900 mL of packed RBCs raised hemoglobin by a mean of 1.2 g/dL and improved 4-km cycling time trial performance by 1.4% in trained cyclists (N=9). 12 That improvement is modest in absolute terms but decisive at the margins of elite stage racing where GC gaps are measured in seconds per day.

Detection

No direct urine or serum test detects autologous transfusion because the reinfused cells are genetically identical to the athlete's own. The ABP flags suspicious haematological fluctuations, particularly the post-transfusion rise followed by a suppression of reticulocyte count as endogenous EPO compensates. 13

Stacking Effects: Why Combined Use Amplifies Individual Gains

The protocol described by USADA witnesses was not use of any single agent. It was coordinated stacking of EPO (for VO2 max), testosterone (for recovery and anabolism), HGH (for lipolysis and connective tissue), corticosteroids (for pain and fat mobilization), and transfusions (for acute hemoglobin loading before key stages). The interaction effects are more than additive in several cases.

EPO and Testosterone Combination Evidence

A study by Baume et al. (2006) in trained male subjects (N=16) showed that combined rHuEPO and testosterone administration over 4 weeks produced a 7.8% improvement in VO2 max vs. 4.9% for EPO alone and 1.8% for testosterone alone. 14 The proposed mechanism is that testosterone upregulates erythropoietin receptor expression on erythroid progenitors, amplifying the EPO stimulus.

The Stage Race Recovery Model

The rationale for stacking in stage racing follows a specific physiological logic. Stage 1 through 5: EPO and transfusion maintain aerobic ceiling. Stages 6 through 14: testosterone and HGH buffer accumulated catabolism and maintain lean mass. Stages 15 through 21 (mountain stages): corticosteroids reduce perceived exertion and mobilize free fatty acids. This phased approach, inferred from USADA testimony and pharmacological half-lives, explains why no single compound captures the full competitive advantage. The USADA document states that the programme was "the most sophisticated, professionalised and successful doping program that sport has ever seen," a direct quotation from its October 2012 reasoned decision.

What Armstrong's Case Tells Clinicians About Long-Term Health Risks

Armstrong was diagnosed with stage 3 testicular cancer in 1996, with metastases to the brain and lungs. He has stated publicly that he does not know whether prior PED use contributed to his cancer diagnosis. That question remains unresolved in the literature, and this article does not make a causal claim. What the literature does document:

Testicular Cancer and Exogenous Androgens

A case-control study published in the British Journal of Cancer (Trabert et al., 2011, N=900) found no statistically significant association between exogenous androgen use and testicular germ cell tumor risk. 15 Testicular cancer is predominantly driven by genetic and developmental factors, with the highest incidence in men aged 20 to 35 regardless of androgen exposure.

Cardiovascular Risk of Chronic EPO Use

Supraphysiologic EPO use raises hematocrit acutely. If haematocrit exceeds 52 to 55%, blood viscosity increases substantially, raising risk of thromboembolic events. A pharmacovigilance analysis of rHuEPO in dialysis patients published in the New England Journal of Medicine (CHOIR trial, N=1,432) showed that targeting hemoglobin above 13.5 g/dL was associated with a significantly higher rate of composite cardiovascular events (HR 1.34, P<0.001). 16 That trial involved patients with pre-existing renal disease, not healthy athletes, but the viscosity mechanism is not population-specific.

Polycythemia and Resting Heart Rate

Several cyclists from Armstrong's era died suddenly at rest from suspected cardiac events. Medical investigators proposed that EPO-driven polycythemia at night, when heart rate slows during sleep, may increase clotting risk. This hypothesis has not been formally proven in a controlled study, but it represents a plausible biological mechanism documented in case reports. 17

The Biological Passport and Modern Anti-Doping: What Changed

The Athlete Biological Passport, introduced by WADA in 2008 and formalized in 2012, shifted anti-doping from direct metabolite detection to longitudinal biomarker surveillance. Instead of catching a single positive test, the ABP builds an individual's haematological and steroidal reference range over time and flags statistically improbable deviations.

Haematological Module

The haematological module tracks hemoglobin, reticulocyte percentage, and OFF-score (hemoglobin minus 60 times the square root of reticulocytes). A WADA-commissioned validation study by Sottas et al. (2011) showed that the ABP detected EPO use with 98% specificity and 83% sensitivity across a simulated competition season at microdose regimens. 18

Would Armstrong's Protocol Pass Today?

This is inference, and it is labeled as such. Based on the pharmacological evidence, microdose EPO cycling and autologous transfusion remain the hardest aspects of the protocol to detect under the ABP because they produce smaller, more gradual haematological shifts. Testosterone micro-dosing remains detectable via CIR testing if a sample is selected for that analysis. The stacked protocol as described by USADA witnesses would be substantially harder to execute undetected under current ABP rules than it was in 1999 to 2005, though not impossible.

Clinical Takeaway for Prescribing Clinicians

Armstrong's case is not an advertisement for PED use. It is a detailed pharmacological record of what coordinated multi-agent doping does to endurance performance and what health risks accumulate. For clinicians managing patients who ask about these agents:

• rHuEPO is FDA-approved only for anemia in CKD, chemotherapy, and HIV-related conditions. Off-label use for performance is not supported by a favorable risk-benefit analysis in healthy individuals. 19
• Testosterone replacement at physiologic doses in confirmed hypogonadal men (morning total T consistently below 300 ng/dL) is guideline-supported. 6 Supraphysiologic dosing carries documented cardiovascular and endocrine risks.
• HGH for non-GH-deficient adults has no FDA-approved indication and carries risk of acromegaly, insulin resistance, and malignancy promotion. 20
• Corticosteroid TUEs should follow WADA TUE criteria: documented medical need, appropriate route and dose, and no reasonable therapeutic alternative.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We recommend against prescribing testosterone therapy to men who desire to maintain their fertility or to improve their sexual function, vitality, or physical performance in the absence of hypogonadism." 6 That guidance applies directly to the performance-directed use documented in Armstrong's case.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% placebo. 21 That trial is cited here as a benchmark for what rigorous RCT evidence of a pharmacological effect looks like, contrasting with the largely observational and witness-testimony basis of performance-doping data. The EPO literature, while mechanistically strong, lacks the randomized trial infrastructure that governs approved therapeutics.

Clinicians managing athletes asking about peptide protocols or performance optimization should document the specific serum levels that define deficiency, use the lowest effective dose targeting physiologic reference ranges, and re-evaluate every 6 months per standard endocrine monitoring protocols.